Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
33.06 USD | -6.99% | -13.04% | +52.74% |
05-15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
05-13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.74% | 1.43B | |
+11.02% | 115B | |
+12.46% | 106B | |
-4.16% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.31% | 17.56B | |
-40.50% | 17.32B | |
+6.29% | 14.03B | |
+31.61% | 12.13B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Transcript : Aeglea BioTherapeutics, Inc. - Special Call